Monopar Therapeutics
ALXN1840
Wilson disease
Resolved
7days ago
Catalyst readout · Jun 30, 2026
What's at stake
A key catalyst for ALXN1840 (Wilson disease) is expected Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“These findings further support Monopar’s planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840 in mid-2026.”